AstraZeneca Invests $2 Billion in Summit Therapeutics for ADC Oncology Trials

Key Facts

1AstraZeneca announced a $2 billion investment in Summit Therapeutics to support Antibody-Drug Conjugate (ADC) oncology trials.

AstraZeneca announced a $2 billion investment in Summit Therapeutics to support Antibody-Drug Conjugate (ADC) oncology trials. Investing.com reported that this capital commitment aims to develop ADC candidates, which represent a high-growth area in oncology, through a strategic partnership between the two companies.

AZN closed at $166.15 on September 28, 2026, while SMMT shares finished at $15.48 on the same date. The investment is designed to accelerate clinical trials for ADC candidates, leveraging Summit's platform to strengthen AstraZeneca's long-term oncology pipeline.